Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Viktor Grünwald, MD, PhD, of Hannover Medical School, reviews the efficacy findings of lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) and sunitinib (Sutent) for the treatment of patients with advanced renal cell carcinoma (RCC) presented during the 2021 American Society of Clinical Oncology Annual Meeting.
In the CLEAR study, investigators noticed an impact in efficacy that was irrespective of the adverse event profile. In terms of progression-free survival, the results were similar in patients who were considered to have favorable risk and those who had at least 1 risk parameter. Grunwald also states that the highest complete responders to the combination were those with favorable risk.
The findings related to the difference between patients with favorable-risk and high-risk advanced RCC are descriptive, notes Grunwald and require further research.
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More